Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
Decreased Efficacy of Levodopa with Carbidopa in Parkinsonian Patients after Adrenal-to-Caudate Implants
Neurol 40:845-846, Tsui,J.K.C.,et al, 1990
Long-Term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease
Neurol 39:1109-1111, Golbe,L.I.,et al, 1989
Clinical, Biochem, & Neuropath of Transplantation of Adrenal Medulla to Caudate Nucleus for Parkinson's
Neurol 39:1227-1234, Jankovic,J.,et al, 1989
Response Variations in the Treatment of Parkinson's Disease
Neurol 34:1507-1509, deJong,G.J.,et al, 1984
Increased Dosage of Carbidopa in Patients with Parkinson's Disease Receiving Low Doses of Levodopa
Arch Neurol 37:146-149, Hoehn,M.M., 1980
Increased Ratio of Carbidopa to Levodopa in Treatment of Parkinson's Disease
Arch Neurol 37:723-726, Tourtellotte,W.W.,et al, 1980
Comparative Effectiveness of Two Extracerebral DOPA Decarboxylase Inhibitors in Parkinson Disease
Neurol 28:964-968, Lieberman,A.,et al, 1978
Juvenile Parkinsonism Treated with Levodopa
Arch Neurol 34:244, Sachdev,K.K.,et al, 1977
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976